Last reviewed · How we verify
Post-operative Ondansetron anti-emesis — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Post-operative Ondansetron anti-emesis (Post-operative Ondansetron anti-emesis) — James Cook University Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Post-operative Ondansetron anti-emesis TARGET | Post-operative Ondansetron anti-emesis | James Cook University Hospital | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Post-operative Ondansetron anti-emesis CI watch — RSS
- Post-operative Ondansetron anti-emesis CI watch — Atom
- Post-operative Ondansetron anti-emesis CI watch — JSON
- Post-operative Ondansetron anti-emesis alone — RSS
Cite this brief
Drug Landscape (2026). Post-operative Ondansetron anti-emesis — Competitive Intelligence Brief. https://druglandscape.com/ci/post-operative-ondansetron-anti-emesis. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab